Bausch Health Companies (TSE:BHC) Shares Down 1.1% – Time to Sell?

Posted by Alanna Baker on Mar 10th, 2026

Bausch Health Companies Inc. (TSE:BHC – Get Free Report)’s share price was down 1.1% during mid-day trading on Monday . The stock traded as low as C$6.97 and last traded at C$7.25. Approximately 421,881 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 559,367 shares. The stock had previously closed at C$7.33.

Analysts Set New Price Targets

A number of equities research analysts have commented on BHC shares. Raymond James Financial upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Monday, December 15th. Barclays raised shares of Bausch Health Companies to a “hold” rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

View Our Latest Analysis on BHC

Bausch Health Companies Stock Down 1.1%

The company has a quick ratio of 0.58, a current ratio of 1.47 and a debt-to-equity ratio of -3,835.02. The stock has a market capitalization of C$2.69 billion, a P/E ratio of 17.26, a PEG ratio of 0.21 and a beta of 0.60. The company has a fifty day moving average price of C$8.70 and a 200-day moving average price of C$9.12.

Bausch Health Companies (TSE:BHC – Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) EPS for the quarter. The firm had revenue of C$6.62 billion for the quarter. Bausch Health Companies had a net margin of 1.82% and a negative return on equity of 20.27%. As a group, research analysts forecast that Bausch Health Companies Inc. will post 5.5472637 EPS for the current fiscal year.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.